Table 2.
Characteristics of primary AML samples from quizartinib-sensitive and quizartinib-relapsed (bold) patients
| Sample | Cytogenetics | Cytogenetic risk group | NPM1 mutation | FLT3 mutation | RUNX1 mutation |
|---|---|---|---|---|---|
| AML-7 | Normal | Intermediate | Mutant | ITD | Not tested |
| AML-7 | Normal | Intermediate | Mutant | ITD | WT |
| AML-14 | t(6;9)(p23;q34.1) | Intermediate | WT | ITD | Not tested |
| AML-14 | t(6;9)(p23;q34.1) | Intermediate | WT |
ITD, D835Y* D835del† |
Not tested |
| AML-15 | +13 | Intermediate | WT | ITD | Not tested |
| AML-15 | +13 | Intermediate | WT |
ITD D835_M837 delinsValLeu‡ |
D93fs§ L110Q|| |
*
c.2503G>T.
†
c.2502_2505delinsC.
‡
c.2504_2509delinsTCT.
§
c.273_277dupCACCG.
||
c.328A>C.